BiotechTube

ALN-AAT02 + Placebo + ALN-AAT02

Phase 1/2Terminated
0 watching 0 views this week💤 Quiet
38
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Conditions

ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Trial Timeline

Dec 5, 2018 → Jun 25, 2020

NCT ID
NCT03767829

About ALN-AAT02 + Placebo + ALN-AAT02

ALN-AAT02 + Placebo + ALN-AAT02 is a phase 1/2 stage product being developed by Alnylam Pharmaceuticals for ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT03767829. Target conditions include ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease.

Hype Score Breakdown

Clinical
13
Activity
8
Company
7
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT03767829Phase 1/2Terminated

Competing Products

20 competing products in ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

See all competitors
ProductCompanyStageHype Score
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
77
MKP10241 + PlaceboMankind PharmaPhase 2
52
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
33
LY3209590 + Insulin DegludecEli LillyPhase 1
33
AC2993Eli LillyPhase 3
77
LY3209590 + PlaceboEli LillyPhase 1
33
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
77
LY2963016 + LantusEli LillyPhase 1
33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
23
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
85
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
36
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
33
Placebo + LinagliptinEli LillyPhase 3
77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
85
teplizumab or placeboEli LillyPhase 1
33
LY2428757 + PlaceboEli LillyPhase 2
52
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
77
LY900014 (SC) + LY900014 (IV)Eli LillyPhase 1
33

Other Products from Alnylam Pharmaceuticals

PatisiranPhase 3
74
PatisiranPhase 3
74
Givosiran + PlaceboPhase 3
74
Nucresiran + Sterile Normal Saline (0.9% NaCl)Phase 3
74
LumasiranPhase 3
74